Orchid Pharma Intrinsic Value
ORCHPHARMA Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹496.86 | ₹447.17 - ₹546.55 | -31.8% | Book Value/Share: ₹248.43, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹320.00 | ₹288.00 - ₹352.00 | -56.1% | Revenue/Share: ₹160.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹291.40 | ₹262.26 - ₹320.54 | -60.0% | EBITDA: ₹36.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹291.40 | ₹233.12 - ₹349.68 | -60.0% | CF Growth: 5.0%, Discount: 15% |
Want to compare with current market value? Check ORCHPHARMA share price latest .
Valuation Comparison Chart
ORCHPHARMA Intrinsic Value Analysis
What is the intrinsic value of ORCHPHARMA?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Orchid Pharma (ORCHPHARMA) is ₹320.00 (median value). With the current market price of ₹728.50, this represents a -56.1% variance from our estimated fair value.
The valuation range spans from ₹291.40 to ₹496.86, indicating ₹291.40 - ₹496.86.
Is ORCHPHARMA undervalued or overvalued?
Based on our multi-method analysis, Orchid Pharma (ORCHPHARMA) appears to be trading above calculated value by approximately 56.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.98 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.33 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -1.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -1.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.48x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Orchid Pharma
Additional stock information and data for ORCHPHARMA
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹19 Cr | ₹6 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹126 Cr | ₹-30 Cr | Positive Operating Cash Flow | 6/10 |
| March 2023 | ₹18 Cr | ₹3 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹93 Cr | ₹93 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹24 Cr | ₹24 Cr | Positive Free Cash Flow | 8/10 |